Extended Data Fig. 5: ctDNA-based MRD testing is Predictive of Response to Adjuvant Chemotherapy in Post-Surgical Patients with Colorectal Cancer.

Kaplan-Meier estimates for disease-free survival stratified by observation (red) and adjuvant chemotherapy (blue) in patients with ctDNA positivity at 4-week after surgery, by stage: A. High-risk stage II patients; B. Stage III patients C. Stage IV patients. Hazard ratio (HR) was adjusted by sex, and performance status. Hazard ratio and 95% confidence interval (CI) were calculated by the Cox proportional hazard model. P-value was calculated using the two-sided log-rank test D. Forest plot depicting the multivariate analysis for recurrence in pathological-stage II-IV ctDNA-positive patients. Various prognostic factors and their association with disease-free survival, as indicated by hazard ratio were analyzed across the cohort using two-sided Wald chi-square test. The unadjusted hazard ratio (squares) and 95% CIs (horizontal lines) are shown for each prognostic factor. Vertical dotted line indicates the null hypothesis.